British Columbia Cancer Agency, BC, Canada.
Radiother Oncol. 2011 Oct;101(1):18-23. doi: 10.1016/j.radonc.2011.05.055. Epub 2011 Jun 23.
The application of biological responses of tumours to predict clinical responses to treatment represents a challenging goal with the potential to inform treatment decisions and improve outcome. If tumour cell death is the result of the inability of a cell to repair complex DNA damage, and if γH2AX foci mark sites of unrepaired double-strand breaks, then it may be possible to use residual γH2AX foci to identify treatment-resistant tumour cells early in the course of therapy. This review will highlight some of the evidence that supports the idea that residual γH2AX foci, within certain limitations, may be useful as an early indicator of tumour response to radiotherapy in situ, either alone or in combination with chemotherapy.
肿瘤的生物反应在预测临床治疗反应中的应用代表了一个具有挑战性的目标，有可能为治疗决策提供信息并改善结果。如果肿瘤细胞的死亡是由于细胞无法修复复杂的 DNA 损伤，如果 γH2AX 焦点标记未修复的双链断裂部位，那么可能有可能在治疗过程的早期使用残余 γH2AX 焦点来识别治疗抵抗的肿瘤细胞。本综述将强调一些支持以下观点的证据，即在某些限制条件下，残余 γH2AX 焦点可能单独或与化疗联合用作原位放射治疗肿瘤反应的早期指标是有用的。
